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STUDY QUESTION: How has the performance of the European regional register of the European IVF-monitoring Consortium (EIM)/
European Society of Human Reproduction and Embryology (ESHRE) evolved from 1997 to 2016, as compared to the register of the
Centres for Disease Control and Prevention (CDC) of the USA and the Australia and New Zealand Assisted Reproduction Database
(ANZARD)?
SUMMARY ANSWER: It was found that coherent and analogous changes are recorded in the three regional registers over time, with a
different intensity and pace, that new technologies are taken up with considerable delay and that incidental complications and adverse
events are only recorded sporadically.
WHAT IS KNOWN ALREADY: European data on ART have been collected since 1997 by EIM. Data collection on ART in Europe is
particularly difficult due to its fragmented political and legal landscape. In 1997, approximately 78.1% of all known institutions offering ART
services in 23 European countries submitted data and in 2016 this number rose to 91.8% in 40 countries.
STUDY DESIGN, SIZE, DURATION: We compared the changes in European ART data as published in the EIM reports (2001–2020)
with those of the USA, as published by CDC, and with those of Australia and New Zealand, as published by ANZARD.
PARTICIPANTS/MATERIALS, SETTING, METHODS: We performed a retrospective analysis of the published EIM data sets span-
ning the 20 years observance period from 1997 to 2016, together with the published data sets of the USA as well as of Australia and New
Zealand. By comparing the data sets in these three large registers, we analysed differences in the completeness of the recordings together
with differences in the time intervals on the occurrence of important trends in each of them. Effects of suspected over- and under-
reporting were also compared between the three registers. X2 log-rank analysis was used to assess differences in the data sets.
MAIN RESULTS AND THE ROLE OF CHANCE: During the period 1997–2016, the numbers of recorded ART treatments increased
considerably (5.3-fold in Europe, 4.6-fold in the USA, 3.0-fold in Australia and New Zealand), while the number of registered treatment
modalities rose from 3 to 7 in Europe, from 4 to 10 in the USA and from 5 to 8 in Australia and New Zealand, as published by EIM, CDC
and ANZARD, respectively. The uptake of new treatment modalities over time has been very different in the three registers. There is a
considerable degree of underreporting of the number of initiated treatment cycles in Europe. The relationship between IVF and ICSI and
between fresh and thawing cycles evolved similarly in the three geographical areas. The freeze-all strategy is increasingly being adopted by
all areas, but in Europe with much delay. Fewer cycles with the transfer of two or more embryos were reported in all three geographical
areas. The delivery rate per embryo transfer in thawing cycles bypassed that in fresh cycles in the USA in 2012, in Australia and New
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Zealand in 2013, but not yet in Europe. As a result of these changing approaches, fewer multiple deliveries have been reported. Since
2012, the most documented adverse event of ART in all three registers has been premature birth (<37 weeks). Some adverse events,
such as maternal death, ovarian hyperstimulation syndrome, haemorrhage and infections, were only recorded by EIM and ANZARD.
LIMITATIONS, REASONS FOR CAUTION: The methods of data collection and reporting were very different among European coun-
tries, but also among the three registers. The better the legal background on ART surveillance, the more complete are the data sets. Until
the legal obligation to report is installed in all European countries together with an appropriate quality control of the submitted data the
reported numbers and incidences should be interpreted with caution.
WIDER IMPLICATIONS OF THE FINDINGS: The growing number of reported treatments in ART, the higher variability in treatment
modalities and the rising contribution to the birth rates over the last 20 years point towards the increasing impact of ART. High levels of
completeness in data reporting have been reached, but inconsistencies and inaccuracies still remain and need to be identified and quanti-
fied. The current trend towards a higher diversity in treatment modalities and the rising impact of cryostorage, resulting in improved safety
during and after ART treatment, require changes in the organization of surveillance in ART. The present comparison must stimulate all
stakeholders in ART to optimize surveillance and data quality assurance in ART.
STUDY FUNDING/COMPETING INTEREST(S): This study has no external funding and all costs are covered by ESHRE. There are
no competing interests.
TRIAL REGISTRATION NUMBER: N/A.
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prematurity
Introduction
On behalf of the European IVF-monitoring Consortium (EIM), it was
decided to compare recorded data dealing with ART in Europe with
those of two other large registers in order not only to assess
achievements but also to study potential deficiencies in the registra-
tion process. EIM was created 20 years ago by European Society of
Human Reproduction and Embryology (ESHRE) and the first set of
data for 1997 was published in 2001 (Nygren and Andersen, 2001).
Since then, annual reports have appeared covering the European ac-
tivities in ART from 1997 to 2016, including a survey describing the
trends over 15 years of ART in Europe (Ferraretti et al., 2017).
Although the first successful treatment with ART was carried out in
Europe (Steptoe and Edwards, 1978), systematic data collection
only started in Europe in 1997. Europe currently consists of 51 inde-
pendent countries with very diverse cultural, political, economic and
legal systems, often lacking national data registers dealing with
reproduction, rendering the Europe-wide registration of activities
in ART difficult. Whereas the first report contained data from
18 countries (Nygren and Andersen, 2001), EIM currently manages
the largest global register, dealing with ART reported by
40 European countries (Wyns et al., 2020).
One way to analyse the quality of the European data register as
managed by EIM is to compare it with large data sets provided by
other sizeable registries that have been active during the same time
period. Similarities and discrepancies between such registries are likely
to be useful to further improve data recording and interpretation. For
that reason, the trends observed in Europe during the time interval
from 1997 to 2016 were compared with those of other large registers,
such as that of the USA (Centres for Disease Control and Prevention
(CDC), with the first data set collected in 1996) and of Australia and
New Zealand (National Perinatal Epidemiology and Statistics Unit, first
data set available online 1996, since 2004 known as the Australia and
New Zealand Assisted Reproduction Database (ANZARD)). The ret-
rospective analysis of the data sets spanning the 20-year observance
period from 1997 to 2016 could help to identify timely trends in the
various techniques of ART.
Materials and methods
Objective and rationale
We performed a retrospective analysis of the published EIM data sets
spanning the 20 years observance period from 1997 to 2016 together
with the published data sets of the USA and those of Australia and
New Zealand, both during the same time interval. The analysis was
carried out to assess newly occurring trends in ART in the three regis-
ters. By comparing the data sets in the three large registers, we ana-
lysed differences in the completeness of the recordings together with
differences in the time intervals between the occurrence of important
trends in each of the three large registers.
Search methods
Since 2001, a total of 18 EIM reports covering the activities in ART
from 1997 to 2014 in all participating European countries have been
published in Human Reproduction. The latest reports dealing with ART
in Europe in 2015 and 2016 were published in Human Reproduction
Open. All data included in the present report have been extracted
from the published data sets, all available online. For comparison pur-
poses we chose the annual data sets with similar degrees of complete-
ness and with a similar multinational organization, i.e. ART activity
register of the USA, published in English by CDC and available online,
and those of Australia and New Zealand, also published in English by
ANZARD and available online. The two other large registers in ART
are the Latin American registry of Assisted Reproduction (RLA)
(Zegers-Hochschild et al., 2020) and the global overview of activities in
ART, published by the International Committee for Monitoring
Assisted Reproductive Technologies (ICMART, Adamson et al., 2018;
De Mouzon et al., 2020).











































.Organization and validation of data
collections
The EIM data register collects data on IVF, ICSI, frozen embryo trans-
fer (FET), egg donation (ED, since 1998), IVM (since 2002), pooled
data on preimplantation genetic testing (PGT, since 2002) and frozen
oocyte replacement (since 2006). In principle, the national registries of
all European countries are welcome to participate. The legal obligation
of single institutions offering ART services to report data to the au-
thorities is very different among different European countries and, as a
consequence, the methods of reporting vary widely. The degree of
participation of the national registries in the EIM-data collection
changes every year, as does the participation of institutions towards
their respective national registries. The collected data governed by the
central office of ESHRE in Grimbergen, Belgium, consists of aggregated
data sets delivered by the participating national registries. The cross-
sectional data were originally collected through a questionnaire, and
later through online software. While in some countries data are
reported in a prospective fashion, cycle by cycle, in other countries ag-
gregated data are reported by each institution every year to their na-
tional register, which then sends the national data sets to the ESHRE-
EIM office. Most countries use their own software systems, if available.
Data quality assurance through external auditing was documented in
some countries, such as Switzerland, where every institution is visited
every second year (Van den Bergh et al., 2005). However, a uniform
quality assurance protocol is not available in Europe. The submitted
data sets have been consistently validated by Veerle Goossens.
In the USA outcome data in ART must be reported annually to the
CDC, which in agreement with the Fertility Clinic Success Rate and
Certification Act (FCSRCA, instituted 24 October 1992) since 1995
collect, analyse and publish data online (www.cdc.gov). Starting in
1997, CDC collaborated with the Society for Assisted Reproductive
Technology (SART) to publish the incoming data. For the purpose of
the current survey, only the data spanning the observation period
from 1997 to 2016 were selected. Details of the history and current
organization of surveillance in ART in the USA as carried out by CDC
have been described recently (Toner et al., 2019). CDC collects data
on ART cycles carried out in virtually all institutions offering ART serv-
ices across the USA. The data are submitted annually by each institu-
tion to the National ART Surveillance System (NASS) using an online
reporting system. Institutions that are members of SART report their
data to NASS via SART, while others report directly to NASS.
Validation of data accuracy needs to be performed by the collecting
institutions. Periodic unannounced inspections of all institutions, includ-
ing the records, as part of the accreditation system are imposed by
public law.
The Australian and New Zealand database on ART (ANZARD)
was initiated in 2004 by the national perinatal epidemiology and statis-
tics unit (NPSU), now located at the University of New South Wales,
Australia, in collaboration with the Fertility Society of Australia.
Australia was the first country worldwide to establish a data registry in
1992 for the purpose of surveillance in ART. The data on ART starting
in 1992 and going up to 2016 are all available online (www.npesu.
unsw.edu.au). Details of the history and current settings of surveillance
in ART in Australia and New Zealand, as carried out by ANZARD,
have been published recently (Chambers et al., 2019). In Australia and
New Zealand, all data on ART and on donor insemination cycles
were reported by each institution offering IVF services as early as
1983 to the supranational data collecting service ACDC (Assisted
Conception Data Collection) and since 2002 to ANZARD (Chambers
et al., 2019). Compulsory data collection and reporting have been car-
ried out as part of accreditation cycle by cycle but since 2009 has de-
veloped towards a woman-based data collection. Data quality
assurance is carried out through annual external auditing of each insti-
tution offering ART services. For the purpose of the current survey,
only the data spanning the observation period from 1997 to 2016
were selected.
Treatment modalities and reported items
The recorded treatments in the three registers are listed in Table I.
Variations in the reporting of treatment outlined together with out-
come data and incident complications in the three registers are pre-
sented in Table II.
Data extraction
European data were extracted manually from the published EIM
reports, which contain cross-sectional data sets published annually in
......................................................................................................
Table I Recorded ART treatment modalities between
1997 and 2016 in the three registers.
Treatment modalities EIM CDC ANZARD
Autologous
IVF 1997 1995 1996
ICSI 1997 1995 1996
FET (IVF þ ICSI) 1997 1995 1996
Freeze-all 2017 2008 2010
eSET not rec.a 2008 1997b
PGT 2002 2006 2004
IVM 2002 not rec. not rec.
FOR 2006 not rec. not rec.
GIFT not rec. 1995 1996
ZIFT not rec. 1995 not rec.
Fertility protection since 2016 not rec. not rec.
Heterologous
ED 1998 1995 1996
Embryo donation 2009 2015c 2004
IVF not rec. not rec. 1996
ICSI not rec. not rec. 1996
Surrogacyd not rec. 2014 2005
a‘not rec.’ means ‘not recorded’.
bBefore 2007, the transfer of a single embryo was recorded only in fresh cycles. It
was not differentiated between elective and non-elective single embryo transfer.
cIn the Centres for Disease Control and Prevention (CDC) data sets, the distinction
is made between frozen and fresh embryo donation.
dThe Australia and New Zealand Assisted Reproduction Database (ANZARD) data
sets denominate surrogacy by the term ‘surrogacy arrangement cycles’, whereas the
CDC denominates surrogacy by the term ‘gestational carrier’.
ED, egg donation; EIM, European IVF-monitoring Consortium; eSET, elective single
embryo transfer; FET, frozen embryo transfer; FOR, frozen oocyte replacement;
GIFT, gamete intra-Fallopian transfer; PGT, preimplantation genetic testing; ZIFT, zy-
gote intra-Fallopian transfer.


































































































Human Reproduction and in Human Reproduction Open (De Geyter
et al., 2020; Wyns et al., 2020). Only the data sets needed to calculate
the proportion of children born after ART and the entire population
of neonates in each European country reporting to EIM were calcu-
lated from the raw data sets, made available by the ESHRE office. The
total numbers of newborn children and of inhabitants of each partici-
pating European country each year were taken from Wikipedia.
The data from the USA were taken from the national summary
reports made available by the CDC on the internet (www.cdc.gov),
where an extended list of reports on annual data (since 2005) are ar-
chived. Between 1997 and 2004, data were taken from the Morbidity
and Mortality Weekly Report (surveillance summaries), published by
CDC. The number of PGT cycles was calculated from percentage val-
ues given in the annual reports.
Annual reports with cross-sectional data on ART in Australia and
New Zealand were obtained from the ANZARD website (www.
npesu.unsw.edu.au) under the title ‘surveillance reports’. Between
1998 and 2001, reports were published bi-annually and the distinction
between events occurring in 1 year and those in the next year was
not always clear, most particularly with respect to pregnancies and de-
liveries after ART.
Statistical analysis
Differences in occurrences in the three geographical areas were ana-
lysed with non-parametric X2 analysis using contingency tables. In
most instances the differences between populations in the three regis-
tries were considerable. In order to better appreciate the degree of
difference, X2 values were given in addition to the P-values. Higher X2
values correspond to higher levels of difference between populations.
Changes in practices over time were analysed with log-rank statistics,




The estimated numbers were calculated with the following formula:
estimated number each year ¼
X
of cases
 number of events per area
number of cases per area
 
The term ‘events’ refers to a particular treatment or adverse event,
whereas the term ‘cases’ refers to the overall population, in which the
event may have occurred.
In all comparisons the degree of freedom ¼ 1.
Results
Contributions of individual ART institutions
and national registries over time
During the observation period (1997–2016), the number of institutions
offering ART services has increased in all three geographical areas.
During this time period, 100% coverage of all treatments was reported
to be maintained continuously only in Australia and New Zealand
(Table III). Between 1997 and 2016, the number of institutions has in-
creased 2.8-fold in Europe (as published by EIM), 2.7-fold in Australia
and New Zealand (as published by ANZARD) and only 1.4-fold in the
USA (as published by CDC). Only EIM provides explicit information
concerning the distribution of the size of institutions offering ART in
participating countries. Over time the number of these institutions
with more than 1000 treatment cycles per year has nearly doubled
(from 11.2% in 2000 to 19.4% in 2016). The number of smaller institu-
tions with fewer than 200 treatment cycles per year decreased from
33.7% in 2000 to 25.2% in 2016 (Supplementary Fig. S1).
More European countries have progressively become members of
EIM: whereas in 1997 only 18 of all 51 European countries (35.3%)
provided data to EIM, the number of participating countries rose to 40
in 2016 (78.4%). As, however, seven (small) European countries do
not harbour any known ART institutions, the degree of completeness
......................................................................................................
Table II Recorded patient characteristics, treatment
outline, outcome data and incident complications.
EIM CDC ANZARDa
Recorded patient characteristics
Age of the female patient Yes Yes Yes
Age of the partner or husband No No Yes
Medical indication for treatment No Yes Yes
Treatment outline
Initiated cycles Yes Yes Yes
Aspiration done or not Yes Yes Yes
Elective single embryo transfer No Since 2008 No
Embryo stage at transfer Yes No Yes
Freeze-all Since 2017 Yes Yes
Cryopreservation technology No No Yes
Number of transferred embryos Yes Yes Yes
Outcome data
Pregnancy Yes Yes Yes
Miscarriage No No Yes
Other abnormal pregnancy outcomes No No Yes
Delivery Yes Yes Yes
Mode of delivery No No Yes
Cumulative outcome data Yes, 1 year No Yes
Multiple delivery Yes Yes Yes
Preterm delivery <37 weeks Yes Since 2011 Yes
Neonatal birthweight No Yes Yes
Neonatal malformation No No Yes
Perinatal mortality No No Yes
Complications
OHSS Yes No Yes
Maternal deaths Yes No 1999b
Haemorrhage Yes No No
Infections Yes No No
Foetal reduction Yes No Yesc
aSee also Table 15.1 in Chambers et al. (2019).
bSix cases of maternal death were mentioned 1999.
cThe number of foetal reductions is combined with terminations of pregnancy.
OHSS, ovarian hyperstimulation syndrome.



















































..reached 93.0% in 2016 (Wyns et al., 2020). The number of European
countries with complete coverage rose from 10 countries in 1997 to
20 in 2016. Among the 20 European countries with complete cover-
age in 2016, 17 reported to have a compulsory registration system
(85%), whereas three had a voluntary registration system (15%). In
contrast, among the 20 European countries with incomplete reporting
only four had a compulsory registration (20%) and 16 a voluntary reg-
istration (80%) (P¼ 0.00039, X2 statistic: 16.942).
Comparison of the recorded ART
treatment modalities 1997–2016
Over the observation period, the array of registered treatment modal-
ities has significantly increased over time in all three registries (Table I).
Whereas some treatment modalities have virtually disappeared, such
as gamete intra-Fallopian transfer and zygote intra-Fallopian transfer,
many more treatment modalities have been added over time, such as
IVM, PGT, ED, surrogacy, and more recently, elective single embryo
transfer (eSET), freeze-all strategy and cell and gonadal tissue freezing
for fertility preservation. ICSI has been recorded by CDC since 1996,
by ANZARD since 1996 and by EIM since 1997. The use of PGT was
first recorded by EIM in 2002, by ANZARD in 2004 and by CDC in
2006. CDC initiated registration of eSET in 2008 and ANZARD in
2010. The freeze-all strategy was first registered by CDC in 2008, by
ANZARD in 2011 and by EIM in 2017.
Numbers of ART treatments 1997–2016
For each therapeutic modality, the treatment numbers recorded by
EIM in Europe, by CDC in the USA and by ANZARD in Australia and
New Zealand are presented in Fig. 1a and in Supplementary Table SI.
In all geographical areas not only the number of treatment modalities
has increased over time, but also the total number of therapeutic
interventions. Whereas IVF, ICSI and FET have remained the dominant
treatment modalities in all three registries, ED became the fourth
most used treatment modality in Europe and in the USA (in 2016:
8.1% in Europe, 11.0% in the USA), whereas in 2016, PGT became
the fourth most used technology in Australia and New Zealand
(9.5%).
The availability of ART in society has previously been defined by the
number of treated couples per million inhabitants and an appropriate
number was set at 1500 treatments per million inhabitants (ESHRE
Capri Workshop Group, 2001; Collins 2002). In 2016, the utilization
of ART in Australia and New Zealand reached 2688 ART treatments
per million inhabitants (78 185 reported treatments per 29 082 100
inhabitants), in the USA 934 (301 672 reported treatments per
323 100 000 inhabitants), in Europe including all countries participating
in the EIM data collection 1220 (918 159 reported treatments per
752 265 824 inhabitants). In 2016, the European countries with com-
plete coverage of all ART treatments reached a utilization level of
1410 (458 404 reported treatments per 325 078 700 inhabitants); in
the European countries with incomplete coverage 1076 (459 755
reported treatments per 323 100 000 inhabitants) (Wyns et al., 2020).
............................................................................................................................................................................................................................



















1997 40 18 45.0 482 335 335 100 35 35 100
1998 41 18 43.9 521 360 360 100 38 38 100
1999 41 22 53.7 537 370 370 100 38 38 100
2000 41 22 53.7 729 569 78.1 383 383 100 41 41 100
2001 41 23 56.1 740 579 78.2 385 385 100 41 41 100
2002 41 22 53.7 770 631 81.9 428 391 91.4 29 29 100
2003 41 28 68.3 1008 725 71.9 437 399 91.3 29 29 100
2004 41 29 70.7 1121 785 70.0 461 411 89.2 34 34 100
2005 41 30 73.2 1134 923 81.4 475 422 88.8 36 36 100
2006 41 32 78.0 1160 998 86.0 483 426 88.2 39 39 100
2007 41 33 80.5 1204 1029 88.7 485 430 88.7 43 43 100
2008 41 36 87.8 1245 1051 84.4 475 436 91.8 43 43 100
2009 41 34 82.9 1179 1005 85.2 481 451 93.8 37 37 100
2010 39 31 79.5 1202 991 82.4 474 443 93.5 37 37 100
2011 41 33 80.5 1314 1064 81.0 481 451 93.8 37 37 100
2012 41 36 87.8 1354 1111 82.1 486 456 93.8 43 43 100
2013 41 38 92.7 1369 1169 85.4 497 467 94.0 43 43 100
2014 42 38 90.5 1419 1280 90.2 498 458 92.0 48 48 100
2015 43 38 88.4 1483 1343 90.6 499 464 93.0 93 93 100
2016 44 40 90.9 1467 1347 91.8 501 463 92.2 94 94 100
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recorded ART in Australia & New Zealand, as given by ANZARD
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ED Embryo donation or Embryo recipient
GIFT Surrogacy arrangment cycles
all recorded ART
(a)
Figure 1. The number of treatments with various forms of ART from 1997 to 2016. ANZARD, Australia and New Zealand Assisted
Reproduction Database; CDC, the Centres for Disease Control and Prevention; ED, egg donation; EIM, the European IVF-monitoring Consortium;
FET, frozen embryo transfer; FOR, frozen oocyte replacement; PGT, preimplantation genetic testing.
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freeze all per aspiration for IVF or ICSI (%) 
X2 p
Europe vs. United States 4.462 <0.05
Europe vs. A&NZ 280 <0.0001
US vs. A&NZ 194 <0.0001
X2 p
United Status vs. 

















no. fresh cycle ET versus no. frozen/thaw cycle ET (ratio)
(b)
Figure 1. Continued.


































































































A shift towards more ICSI instead of conventional IVF gradually
took place in all three geographical areas (Fig. 1b; A): in Australia and
New Zealand, ICSI became more frequently used than IVF in 1999, in
the USA in 2000 and in Europe in 2002. Using log-rank statistical
analysis the differences in the evolution of the use of IVF with respect
to ICSI in the three geographical areas are significant: between Europe
and USA, the X2 test statistic was 4.462 (P< 0.05), between Europe
and Australia and New Zealand 280 (P< 0.0001) and between the
USA and Australia and New Zealand 194 (P< 0.0001).
In addition, the ratio of fresh over thawing cycles is evolving similarly
in the three geographical areas. The number of FET cycles started to
prevail over fresh treatments in 2016 in Australia and New Zealand
and in 2015 in the USA (Fig. 1b; B). In Europe, the number of FET
cycles was still less prevalent than fresh transfers in 2016.
Finally, a sharp rise in the number of freeze-all cycles is observed
both in Australia and New Zealand (reaching 26.5% of all oocyte re-
trieval cycles for IVF and ICSI in 2016) and in the USA (19.2% in
2016). Although the evolution of the numbers of freeze-all cycles in
the USA and in Australia and New Zealand seems similar, log-rank
statistics revealed a statistically significant difference (X2 analysis 183.5,
P< 0.0001). The pickup of freeze-all is taking place in Europe as well,
although with a clear delay (8.5% in 2016) (Fig. 1b; C).
Relationship between the reported
numbers of initiated treatments,
aspirations for oocyte collection and
embryo transfers
During the observation period, the recorded numbers of initiated
treatments, oocyte retrievals (aspirations), and embryo transfers in
each of the three geographical regions were compared in order to as-
sess the validity of submitted data on treatment numbers
(Supplementary Table SII). In the European data sets, the logic in the
sequence of events (higher numbers of initiated cycles compared to
the numbers of aspirations and higher numbers of aspirations com-
pared to numbers of embryo transfers) was true in only 4 of 20 years.
In 16 reported years, the number of initiated cycles did not fit to the
number of reported aspirations or to the number of embryo transfers
(as marked by asterisks in Fig. 2 and Table IV). In 2007, the reported
number of embryo transfers even exceeded the number of initiated
cycles and the number of aspirations (Fig. 2). This is caused by a num-
ber of large European countries in which the number of initiated cycles
has consistently not been reported. Both in the USA and in Australia
and New Zealand this requirement was fulfilled during all 20 years of
reporting.
The reported numbers of initiated treatment cycles varied among
European countries (Table IV). In the 4 years with higher reported
numbers of initiated treatment cycles, the proportion of reporting
European countries varied between 86.4% and 100%.
In the USA fewer embryo transfers during fresh cycles were
reported since 2010, in Australia and New Zealand since 2012 and in
Europe since 2016 (Fig. 2).
Embryo transfer policy 1997–2016
Changes over time in the number of embryos transferred per treat-
ment cycle are depicted in Fig. 3 and full data are provided in
Supplementary Table SIII. Whereas in the European data sets the
number of embryos transferred is given both in fresh and in FET
cycles, the Australian and New Zealand data sets provide those data
from 2007 onwards. Before 2007, the number of embryos per transfer
was available from fresh cycles only. The US data sets provide infor-
mation about the number of embryos transferred in fresh cycles from
2005 onwards (not FET cycles).
In all three geographical areas, there is a clear trend towards the
transfer of fewer embryos (Fig. 3). In Australia and New Zealand, the
trend towards the transfer of a single embryo started as early as in
2000, whereas this shift was taking place in Europe and in the USA
more gradually. The transfer of three or more embryos per treatment
was virtually abandoned in Australia and New Zealand in 2006. The
practice of transferring three or more embryos per treatment has pre-
vailed only in the USA.
Pregnancy outcomes 1997–2016
Changes over time in the delivery rates both in fresh and in FET cycles
are given in Fig. 4 and Supplementary Table SIV. The Australian and
New Zealand registry provided data on the number of deliveries after
FET cycles systematically from 2002 onward. The outcome results
were similar in Europe and in Australia and New Zealand. The delivery
rates in fresh and FET cycles, achieved in the USA were consistently
higher than in the two other geographical areas (Fig. 4). The delivery
rate per number of embryos transferred was not obtained in this
survey.
In all three geographical areas, the numbers of deliveries achieved
after FET cycles have been on the rise. The number of deliveries after
FET cycles started to exceed those after fresh cycles in 2012 in the
USA, and in 2013 also in Australia and New Zealand. In Europe, this
marking point has not yet been reached.
In parallel, the number of multiple deliveries, both of twins and trip-
lets, has decreased in all three geographical areas during 1997–2016
(Supplementary Table SV and Supplementary Fig. S2). Whereas triplet
deliveries were the first to virtually disappear from the recorded data
sets, the delivery rates of twins started to decrease much later.
Neonatal and infant outcomes 1997–2016
In all three geographical areas, the number of children born after ART
was registered (in numbers) along with the ratio between children
born after ART and all children born in the respective geographical
areas (in %). As depicted in Fig. 5, the absolute number of children
born (Fig. 5A) and the ratio between the number of neonates from
ART over all neonates (Fig. 5B) tended to rise constantly during the
20-year observation period. The steepest increase in the number of
newborn children after ART is observed in Europe, with the lowest in-
crease in Australia and New Zealand. The highest proportion of new-
born children after ART is being observed in Australia and New
Zealand, reaching 4.1%. The European countries with the highest pro-
portion of newborn children after ART in 2016 were Spain (7.7%) and
Austria (6.2%, Wyns et al., 2020). In the same year, the European
countries with the lowest proportion of children after ART were
Lithuania (0.1%) and Serbia (0.2%, Wyns et al., 2020).
Except for the gender of the children, which is continuously being
recorded in the Australia and New Zealand register, none of the three
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Figure 2. The number of initiated fresh cycles with IVF 1 ICSI, the number of aspirations of oocytes and the number of cycles
with embryo transfers.


































































































registers record any information about the long-term health status of
the children born after ART beyond the moment of birth.
Adverse events 1997–2016
Adverse events are recorded as complications observed during or
after ART, such as ovarian hyperstimulation syndrome (OHSS),
infections and haemorrhage after oocyte collection, foetal reduction
and maternal death (Table V). CDC does not deliver any informa-
tion concerning these complications but mentions the rare occur-
rence of maternal deaths. In the Austrialia and New Zealand data
sets both the incidence of OHSS (only those cases that had to be
admitted to a hospital) and of foetal reduction (combined with ter-
mination of pregnancy) are provided, albeit intermittently. Over the
entire observation period the mean incidence of OHSS in Europe
was reported to be 0.61% and in Australia and New Zealand 0.71%
(X2 statistic is 171, P< 0.00001). In recent years the incidence of
OHSS has decreased both in Europe and in Australia and New
Zealand (Table V). The incidence of haemorrhage after oocyte col-
lection has been fairly constant both in Europe and in Australia and
New Zealand. The reported numbers of infections and of foetal
reductions have been fluctuating throughout the observation period.
Maternal deaths were reported systematically only in Europe and
these were rare events.
Premature deliveries 1998–2016
Data on the incidence of premature delivery (before 37th week of
gestation) have been recorded for variable time periods in the three
geographical areas (Fig. 6). The percentages of prematurity were taken
from the data in Supplementary Table SV of each published EIM report
(which also includes premature deliveries after ED) and recalculated
from the delivery numbers after IVF, ICSI and FET, thereby assuming
that premature delivery rates were similar in all four treatment modali-
ties. The incidence of prematurity evidently depends on the degree of
multigestation, but differences in the reported incidences of prematu-
rity are observed in the three geographical areas. Because the prema-
ture delivery rates in the three areas were becoming more similar
from 2014 to 2016, we analysed the quantitative differences during
that time interval using log-rank analysis (insets in Fig. 6). Whereas the
prematurity rates in triplet deliveries were similar in the three geo-
graphical areas, reported singleton and twin prematurity rates were
highly distinct in the three geographical areas. Australia and New
Zealand had the lowest rate of premature births for singleton gesta-
tions, but the highest rate for twins and triplets. Since 2006, the
reported prematurity rates of singletons in the European data sets
rose to incidence levels similar to those in the USA, whereas the
reported prematurity rates in twin and triplet pregnancies remained
the lowest of the three regions.
Discussion
In 1999, ESHRE created the EIM and published in 2001 the first data
set of the European survey on ART, performed in 1997 (Nygren and
Andersen, 2001). Since then, annual reports have appeared with data
sets that have become increasingly more complete over time
(Table III). Although these surveys remain largely descriptive, the ulti-
mate aim of data recording in medicine in general, and in ART in par-
ticular, is to establish both surveillance and vigilance (De Geyter and
Adashi, 2019; De Geyter, 2019). ART is still a young technology and
prone to many changes that are in many instances swiftly and widely
adopted by the subspecialist community, but often without adequate
proof of safety. Although prospective randomized trials are the best in-
strument to demonstrate improvements in treatment strategies, it
takes much time to plan and carry them out and they are often under-
powered for small effects or subpopulations. Registry data are a valu-
able adjunct to randomized studies and to meta-analyses, as they have
the potential to demonstrate ongoing changes under real-life condi-
tions based on data sets arising from large cohorts. However, the
quality of the recorded data must be optimized, particularly in Europe
with its very fragmented political and legal landscape (Calhaz-Jorge
et al., 2020).
After 20 years of data collection the steering committee of EIM de-
cided, on behalf of ESHRE, to compare the existing and published EIM
data sets with those of two other comparable regional registries,
namely CDC and ANZARD, using the annual cross-sectional data
sets, all published and freely available online. Whereas in the USA
(FCSRCA) and in Australia and New Zealand (Reproductive
Technology Accreditation Committee) data registration is compulsory,
the regulations in the various European countries continue to be highly
diverse (Calhaz-Jorge et al., 2020).
......................................................................................................





initiated fresh cycles (no)
%
1997* 18 16 88.9
1998* 18 13 72.2
1999 22 19 86.4
2000 22 22 100
2001* 23 21 91.3
2002* 25 22 88.0
2003* 28 25 89.3
2004* 29 23 79.3
2005* 30 26 86.4
2006* 32 29 90.6
2007* 33 27 81.8
2008* 36 31 86.1
2009* 34 30 88.2
2010* 31 29 93.5
2011* 33 33 100
2012* 34 26 76.5
2013* 38 34 89.5
2014* 39 32 82.1
2015 38 36 94.7
2016 40 38 95.0
The asterisks (*) mark the years in which the number of initiated cycles is underre-
ported (Fig. 2).
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transfer of two embryos
Figure 3. Proportion of single embryo transfers, transfers with two embryos and transfers with three or more embryos.































delivery rate per embryo transfer in fresh cycles









































Figure 4. Deliveries per embryo transfer in fresh cycles and in thawing cycles. The arrows point towards the year in which the number
of deliveries after thawing cycles exceed the number of deliveries after fresh cycles.
















































Number of infants born after ART
Europe
United States































































Figure 5. Changes in the numbers of infants born after IVF, ICSI and FET.



















































..The comparison of the three registries revealed a number of defi-
ciencies that are closely linked to the methods used in national and su-
pranational data registries. Although an increasing array of novel
technology has been introduced and adopted by the three registries
(Tables I and II), large national or supranational registries are slow to
initiate recording them. Most if not all emerging novel treatment mo-
dalities were initiated after key publications, such as the first birth after
ICSI (Palermo et al., 1992). ICSI was recorded by all registries from
their early beginnings, for example by CDC since 1996, by ANZARD
since 1996 and by EIM since 1997. PGT was first introduced for ge-
netic analysis of the X-chromosome in a human embryo (Handyside
et al., 1990) and its use was first recorded by EIM in 2002, by
ANZARD in 2004 and by CDC in 2006. The feasibility of eSET was
first suggested as an appropriate treatment in 2001 (Tiitinen et al.,
2001) and its use was registered by CDC in 2008, and by ANZARD
in 2010. In the European data sets, the transfer of one embryo is being
recorded, but not whether this embryo stems from eSET in particular.
Freeze-all was first described 1999 (Ferraretti et al., 1999) and was
first registered by CDC in 2008, by ANZARD in 2011 and by EIM in
2017. In general, new developments in ART have been picked up by
EIM later than CDC and ANZARD. There is no indication that the
adoption of novel technology into the recording of data is orchestrated
among the three registers.
In times in which many adjuncts, with limited or no evidence of suc-
cess, are constantly being introduced into ART (Harper et al., 2017),
the complexity of present-day ART is barely reflected by current sim-
plified data recordings. It is crucial that the structure of the published
cross-sectional data sets remains comparable from one year to an-
other. Furthermore, the ever more complex mixture of new evolving
techniques and treatment options does pose a challenge to any data
registry. Gamete and embryo donation, fresh or FET, transfer at differ-
ent stages of embryonic development, genetic testing options at differ-
ent levels of gamete and embryonic development, and the extraction
of gametes at different stages of development out of the ovaries or
from testicular tissue all contribute to the current variability of treat-
ment options. In addition to a constantly updated and unified glossary
(Zegers-Hochschild et al., 2017), we need to set up a well-structured
and systematic catalogue of present-day (and possibly foreseeable)
treatment modalities that can be adapted easily with time while main-
taining the overall structure of the ongoing data collections and annual
reports.
The first aim of all national and supranational registers has tradition-
ally been to record completely and accurately all possible treatment
numbers and outcomes at different stages of the process and to come
up with a coherent descriptive analysis (Adamson et al., 2018).
Intention-to-treat is an important variable that allows us to understand
and evaluate the effects of dropouts or cycle cancellations and of con-
versions to other treatment modalities: both impact on the final out-
come results. In contrast to the Australian and New Zealand and the
US data sets, the number of reported treatments, most particularly ini-
tiated treatments, in the European data sets was incomplete during 16
of the 20 years of this survey (Fig. 2), resulting in an underrepresenta-
tion of the number of initiated cycles in comparison to the number of
oocyte retrievals. As a result of incomplete data reporting, the
............................................................................................................................................................................................................................
Table V Recorded complications after ART.
EIM ANZARD
Year OHSS Haemorrhage Infection Foetal reduction Maternal death OHSS Foetal reduction
1997 18
1998 153 (1.1) 6
1999 1083 (0.6) 84 (0.04) 30 (0.02) 121 (0.7)
2000 1586 (0.8) 388 (0.19) 36 (0.02) 256 0 113 (0.7) 14
2001 1851 (0.9) 394 (0.19) 24 (0.01) 391 1
2002 2148 (0.9) 622 (0.26) 227 (0.09) 461 2 192 (1.1) 58
2003 2646 (1.1) 799 (0.29) 135 (0.05) 480 2 218 (1.1) 50
2004 2858 (1.1) 520 (0.20) 362 (0.14) 526 4 300 (1.4) 49
2005 3347 (1.1) 523 (0.17) 207 (0.07) 436 0 306 (1.2) 60
2006 2753 (0.8) 544 (0.16) 42 (0.01) 466 2 240 (0.9) 76
2007 2470 (0.7) 574 (0.17) 64 (0.02) 364 3 244 (0.8)
2008 2947 (0.6) 652 (0.13) 49 (0.01) 394 1 198 (0.6)
2009 2137 (0.6) 415 (0.11) 61 (0.02) 484 1 259 (0.7)
2010 1500 (0.4) 641 (0.17) 53 (0.01) 441 2 206 (0.6)
2011 1705 (0.5) 711 (0.17) 59 (0.01) 343 1 229 (0.7) 99
2012 1953 (0.5) 848 (0.20) 101 (0.02) 485 3 266 (0.7) 105
2013 1845 (0.4) 793 (0.18) 78 (0.02) 416 2 294 (0.7) 106
2014 2039 (0.4) 919 (0.19) 108 (0.02) 526 3 274 (0.7) 94
2015 2167 (0.4) 946 (0.19) 114 (0.02) 501 2 211 (0.5) 115
2016 1928 (0.4) 983 (0.19) 117 (0.02) 553 0 215 (0.5) 177
CDC did not deliver any numbers on adverse events occurring in the USA.
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triplet or higher grade gestation birth rate <37 weeks
X2 p
Europe vs. USA 43.5 <0.0001
Europe vs. A&NZ 414.1 <0.0001
USA vs. A&NZ 238.0 <0.0001
X2 p
Europe vs. United States 192.3 <0.0001
Europe vs. A&NZ 14.156 <0.0001
USA vs. A&NZ 14.2 <0.0001
X2 p
Eur. vs. USA 0.325 n.s.
Eur. vs. A&NZ 0.028 n.s.





Figure 6. Changes in the proportion of premature deliveries (in singleton, twin and triplet (or higher grade)) pregnancies
after ART.


































































































outcome of ART for these years can only be related to the number of
retrievals, not to the number of initiated cycles. The EIM registry con-
sists of the national representatives of all participating European coun-
tries. Europe is made up of a high diversity of countries with very
different cultural, political and legal systems. The lack of unifying struc-
tures and, often, the absence of any requirement for national data reg-
istration, renders the undertaking of a systematic collection of data on
ART particularly difficult. In a number of European countries, the num-
ber of initiated cycles remained unreported for many years. Owing to
better awareness and improved data collection, more countries are
now delivering more complete and validated data sets to EIM
(Table IV).
In the USA, the highest number of initiated cycles per year was
reported in 2008 and these numbers have declined since then (Fig. 2).
These changes are paralleled by rising numbers of oocyte, and fresh
and frozen embryo donations (Fig. 1a), suggesting a shift of conven-
tional IVF and ICSI to donation cycles in a significant proportion of
patients since 2008. Although the selection towards good prognosis
cases may be linked to the higher delivery rates seen in the USA in
conventional fresh IVF and ICSI, as discussed elsewhere (Kushnir et al.,
2016, 2017), other factors, such as the number of embryos transferred
per cycle, may be involved in contributing to the observed higher de-
livery rates in the USA. The delivery rate per number of transferred
embryos was not analysed in this survey.
Since 2010–2012, in all three regions the number of initiated cycles
(as far as available in the EIM data set), the number of oocyte retriev-
als and the number of embryo transfers in fresh IVF and ICSI cycles
has declined (Fig. 2). In agreement, the proportion of FET cycles
started to increase around the same time period (Fig. 1b; B),
Concomitantly, the practice of freeze-all emerged in the USA and in
Australia and New Zealand (Fig. 1b; C). This shift towards more freez-
ing and thawing cycles resulted in more deliveries after FET cycles,
which first exceeded the number of deliveries after fresh cycles in the
USA, then in Australia and New Zealand, and probably soon in
Europe as well (Fig. 4). Despite all of the problems with data registra-
tion and recording, these trends can clearly be visualized in all three
registries and establishes their high value in demonstrating ongoing
trends in ART.
Under- and over-reporting of adverse events lead to either over- or
under-estimation, respectively, of the safety of interventions. The com-
parison of the recorded data on complications and the distinct inci-
dence of various adverse events in the three registries during the 20-
year observation period are likely related to over- and under-
reporting. The incidence of OHSS has been determined prospectively
and the degree of severity of the syndrome may vary, but approxi-
mately 2.5–2.9% of all women undergoing treatment with conventional
ART suffer of at least one episode of OHSS (Malchau et al., 2019).
Both EIM and ANZARD reported a mean incidence of OHSS be-
tween 0.61% and 0.71% per treatment cycle (Table V), which suggests
under-reporting. In addition to over- and under-reporting of adverse
events, the lack of standardization in defining complications in ART is a
major obstacle. The international glossary on definitions may help to
standardize the reporting of adverse events (Zegers-Hochschild et al.,
2017).
Another example of potential under-reporting is given by the signifi-
cantly lower reported incidence of premature deliveries in twin and
triplet gestations in the European register. In recent years, however,
the number of recorded premature twin and triplet deliveries in
Europe is now approaching the long-standing incidences reported by
CDC and ANZARD (Fig. 6). In the beginning of ART data recordings
in Australia and New Zealand, some degree of under-reporting of pre-
mature twin and triplet pregnancies may have prevailed as well.
Over-reporting may also occur. A comparison of recording ART in
the case of normal pregnancies in birth certificates with national ART
surveillance data in FL and MA, USA, has demonstrated a clear discor-
dance between both data registries: ART was more often reported
for women at risk of adverse pregnancy outcome, but much less so in
normal pregnancies (Cohen et al., 2014). The higher incidence of pre-
mature deliveries in singleton pregnancies in the USA than in Australia
and New Zealand may perhaps be explained by some under-reporting
of normal delivery outcomes in the US data sets.
Even worse than over- or under-reporting, a number of known
complications of ART are, even today, still not being registered sys-
tematically, such as accidental loss of gametes and embryos (not regis-
tered at all), infections and bleedings (recorded only by EIM) and
maternal death (recorded annually only by EIM). Complications during
ongoing pregnancies achieved with ART, such as hypertensive disor-
ders after infertility treatment (Monseur et al., 2019), are not being
recorded systematically by any register. The health status of the infants
is recorded only at the moment of birth, although minor and major
malformations or health impairments are more often determined dur-
ing further infant development. Long-term outcomes of children con-
ceived with ART might be better evaluated through linking of ART
data sets with the data sets of other health services, as done in the
USA and in the European Nordic countries (Luke et al., 2019).
Despite these data recording deficiencies, which become apparent
when comparing the results of the three registries over a prolonged
time interval, much has been achieved in the last 20 years. Between
1997 and 2016, the number of recorded treatments with ART by EIM
in Europe has multiplied by a factor of 5.3 (in the USA by CDC: 4.6,
in Australia and New Zealand by ANZARD: 3.0) (Fig. 1a). During the
same time period, the number of recorded treatment modalities has
increased in Europe from three to seven. The high impact of ART in
Europe together with a level of utilization reaching 1410 treatments
per 1 million inhabitants in countries with complete coverage (from a
medical point of view the optimal goal being at least 1500 treatments
per 1 million inhabitants, ESHRE Capri Workshop Group, 2001;
Collins 2002) resulted in 2.9% of infants born after ART in Europe in
2016 (in the USA: 1.9%, in Australia and New Zealand: 4.1%) (Fig. 5).
Many ongoing trends can be observed, both in time and in quantity,
such as the shift from conventional IVF to ICSI (Fig. 1b; A), the increas-
ing preponderance of FET or cryo-cycles versus fresh cycles (Fig. 1b;
B) and the progressive adoption of ‘freeze-all’ (Fig. 1b; C). Those
changes in attitudes in the three geographical areas impact on treat-
ment outcomes, such as more deliveries now taking place after thaw-
ing cycles than after fresh cycles in the USA and in Australia and New
Zealand, but not yet in Europe (Fig. 4). These results demonstrate a
rising reliance on freezing and thawing of embryos as a technique,
which has been recorded from the early beginnings of the three regis-
ters. In consequence, fewer embryos are now being replaced per
treatment trial (Fig. 3) resulting in fewer twin and triplet deliveries
(Supplementary Table SV and Supplementary Fig. S2). Although these
developments can be observed as they take place in the three geo-
graphical areas, the pace is set by Australia and New Zealand, which


































































































was the first to predominantly adopt a SET policy and which was the
first to push the twin delivery rates below 5% in 2013. In all three
regions, triplet deliveries have practically vanished since 2012.
Unfortunately, none of the registers allow us to check this change in
practice on the health status of the infants. For that we have to rely
on studies linking ART surveillance data sets with other health services
data sets (Luke et al., 2019).
To summarize, and to provide suggestions for improvements, the
comparison of three large registers in ART clearly demonstrates that
surveillance in ART is working. In all three registers, the number of
main developments in ART are both identified and quantified, and
some of these developments result in lowering the incidence of ad-
verse events or in improving the outcome of pregnancies. However,
the current concept of surveillance in ART through national or supra-
national registries is not without deficiencies. Instead of the current
cross-sectional approach, the cumulative approach of modern ART
requires more continuous recording systems in which the various ther-
apeutic and outcome steps of each couple or individual can be linked
together over prolonged time periods, in different institutions and
across borders. It will be crucial to install a central European data col-
lection system based on individual patients and/or couples to monitor
their path through different treatments and institutions prospectively
(De Geyter et al., 2016). This may be achieved by installing electronic
healthcare records of individual couples or persons, which store all the
complex data arising from ART and that ultimately can be used to add
pregnancy-related and obstetric outcome data (Pandey et al., 2012).
Incorporating electronic health records has been demonstrated to be
beneficial in surveillance and vigilance (Kruse et al., 2018). Such an ap-
proach may be time-saving, by avoiding having to write extensive doc-
umentation and by improving the workflow, thereby resulting in better
productivity (Kruse et al., 2018). Whereas the health authorities and/
or professional societies of some European countries have already de-
veloped adapted software systems to collect data from their respec-
tive institutions offering ART (including plausibility testing of the
incoming data), others have not. Therefore, the centralized European
data collecting office must use a software system that can be linked to
those of the national authorities and/or professional societies.
Comparisons of outcome data on an individual patient level highlight
the limitations of registries (De Neubourg et al., 2016), necessitating
appropriate validation standards of submitted data sets (Wilkinson
et al., 2017; Bacal et al., 2019). Of course, confidentiality and protec-
tion of privacy must be safeguarded, and traceability of submitted data
should be organized in full compliance with legal regulations. Electronic
health data resulting from extensive diagnostics and treatments in
medically assisted reproduction must be made the property of the
patients (and their offspring) for documentation purposes and for long-
term outcome monitoring of both the patients and their offspring. Not
only professional societies should be interested in such an accurate, far
reaching and transgenerational healthcare monitoring system in ART,
but also governmental organizations and the lay public.
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